Skip to main content
OpenTrials
Completed

NCT Number: NCT02556177

Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2

This is an open-label, non-randomized, prospective, multi-site, parallel group (segment), hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical neuropsychological assessments and GE Research Pack II advanced MR imaging in mTBI patients. The results are primarily intended for scientific inquiry and engineering development purposes, and may be used in future regulatory submissions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California-San Diego, San Diego, California, United States

Loading trial locations.

About this study

This data-driven study is being conducted for hypothesis generation in population of mild traumatic brain injury (mTBI) patients using advanced applications for magnetic resonance imaging (MRI) developed by the Sponsor, GE Healthcare (GEHC), and corresponding clinical neuropsychological assessments. This data is intended for future use in development of specialized MR acquisition, reconstruction, and processing software intended to identify mTBI biomarkers.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects included as mTBI patients (Segment 1) will:

  • Be aged ≥15 and ≤50 years old at the time of enrollment;
  • Be diagnosed with mTBI according to the standard diagnostic procedures at the investigational site in a timeframe that meets enrollment criteria for enrollment within 72 hours (Visit 1) or 7±2 days (Visit 3) from injury.
  • Be capable of sufficiently clear communication and language fluency to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors, and to complete study assessments (as per Section 6.3 - Protection of Vulnerable Subjects) for participation in all parts of the study.

Subjects included as non-mTBI controls (Segment 2) will:

  • Be aged ≥15 and ≤50 years old at the time of enrollment;
  • Are of similar characteristics as the mTBI population in terms of gender, age, handedness, educational level, and scanner criteria (as per Section 6.1.1 Enrollment of non-mTBI controls)
  • Be capable of sufficiently clear communication and language fluency to allow the subject to provide written informed consent, or assent with parental or guardian consent for minors, and to complete study assessments (as per Section 6.3 - Protection of Vulnerable Subjects), for participation in all parts of the study.

Exclusion criteria

Subjects will be excluded that have: mTBI

  • Loss of consciousness (LOC) ≥5 minutes;
  • Posttraumatic amnesia lasting ≥24 hr following mTBI;
  • Current or prior (within past 10 years) moderate to severe TBI
  • Diagnosis of mTBI within the past 6 months;
  • Epilepsy with recurring seizures in past 10 years;
  • Drug abuse (except marijuana) in past 10 years based on DAST-10 screening;
  • Alcohol abuse based on AUDIT-C screening;
  • Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix C - Screening Axis I/II Disorders):
  • History of brain mass, neurosurgery, stroke, white matter disease, and/or dementia;
  • Known cognitive dysfunction or structural brain disease/malformation;
  • Structural brain injury on prior neuroimaging findings;
  • Been prescribed antipsychotic/antiepileptic medications;
  • Unable (such as due to urgent medical care needs) or unwilling to complete study procedures accurately or have any conflict of interest that could affect study results, in the opinion of the investigator;
  • Contraindications to MRI scanning, including:
  • Current or suspected pregnancy, per site practice;
  • Other conditions that may constitute a hazard to the subject during study participation, per investigator;
  • Inability to comply with any part of the site's MR safety policy.

Subjects will be excluded that have:- non-TBI (controls)

  • Diagnosis of mTBI within the past 6 months;
  • Prior (within past 10 years) moderate to severe TBI (GCS <13);
  • Epilepsy with recurring seizures in past 10 years;
  • Drug abuse (except marijuana) in past 10 years based on DAST-10 screening;
  • Alcohol abuse based on AUDIT-C screening;
  • Current primary Axis I or II psychiatric disorders, except for disorders classified as minor and not expected to impact study conduct or integrity (as detailed in Appendix C - Screening Axis I/II Disorders):
  • History of brain mass, neurosurgery, stroke, white matter disease, and/or dementia;
  • Known cognitive dysfunction or structural brain disease/malformation;
  • Structural brain injury on prior neuroimaging findings;
  • Been prescribed antipsychotic/antiepileptic medications;
  • Unable (such as due to urgent medical care needs) or unwilling to complete study procedures accurately or have any conflict of interest that could affect study results, in the opinion of the investigator;

Treatment and study plan

MRI

Procedure

MRI scanning

Primary outcomes

  1. MRI Image Data Sets

    Time frame: Per patient scanning over 3 months

    MRI image data sets collected from subjects who completed the study.

  2. Neuropsychological Assessments

    Time frame: Per patient scanning over 3 months

    Neuropsychological assessments collected from subjects who completed the study.

Sponsors and collaborators

Lead sponsor

GE Healthcare

Industry

Collaborators

  • ICON plc

Registry information

Acronym: mTBI-phase2

Important dates

Study start
2015
Primary completion
2018
Study completion
2018
First posted
Sep 22, 2015
Registry last updated
Sep 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.